Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.88 |
| ▸ | F10 | P00742 | 3/20 | 0.88 |
| ▸ | PRMT1 | Q99873 | 5/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.47 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.47 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5034833 | 0.98 | F2 (0.85) | F2F10PRMT1ITGB3ITGA2B | |
| SCHEMBL5032861 | 0.98 | F2 (0.85) | F2F10PRMT1ITGB3ITGA2B | |
| SCHEMBL7979967 | 0.98 | F2 (0.85) | F2F10PRMT1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL5031493 | 0.97 | F2 (0.82) | F2F10PRMT1ITGB3ITGA2B | |
| SCHEMBL5028071 | 0.97 | F2 (0.88) | F2F10PRMT1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL5034703 | 0.95 | F2 (0.85) | F2F10PRMT1ITGB3ITGA2B | |
| SCHEMBL237460 | 0.93 | F2 (1.00) | F2F10PRMT1TPSAB1TPSD1 | |
| Hydrochloric Acid SCHEMBL5028046 | 0.92 | F2 (0.97) | F2F10PRMT1TPSAB1TPSD1 | |
| SCHEMBL7978262 | 0.92 | F2 (0.74) | F2F10PRMT1ITGB3ITGA2B | |
| SCHEMBL18296495 | 0.87 | F10 (0.72) | F2F10PRMT1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689732-A4 | CATIONIC SUBSTITUTED BENZOFURANS AS ANTIMICROBIAL AGENTS | UNIV NORTH CAROLINA (US) | 2008-10-22 | — | — | EP | claimed |
| US-20080114047-A1 | Cationic substituted benzofurans as antimicrobial agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-15 | — | — | US | claimed |
| EP-1689732-A2 | CATIONIC SUBSTITUTED BENZOFURANS AS ANTIMICROBIAL AGENTS | The University of North Carolina at Chapel Hill (US) | 2006-08-16 | — | — | EP | claimed |
| US-20050197378-A1 | Cationic substituted benzofurans as antimicrobial agents | TIDWELL RICHARD R (US) | 2005-09-08 | — | — | US | claimed |
| WO-2005055935-A2 | CATIONIC SUBSTITUTED BENZOFURANS AS ANTIMICROBIAL AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-06-23 | — | — | WO | claimed |
| WO-2001072742-A1 | BISAMIDINO COMPOUNDS AS NHE-3 INHIBITORS | MERCK PATENT GMBH (US) | 2001-10-04 | — | — | WO | claimed |
| EP-1689732-A4 | CATIONIC SUBSTITUTED BENZOFURANS AS ANTIMICROBIAL AGENTS | UNIV NORTH CAROLINA (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080221191-A1 | Cationic substituted benzofurans as antimicrobial agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-11 | — | — | US | disclosed |
| US-7417158-B2 | Mycobacterium tuberculosis infection; protozoan pathogens; fungal pathogens | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080114047-A1 | Cationic substituted benzofurans as antimicrobial agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-15 | — | — | US | disclosed |
| EP-1689732-A2 | CATIONIC SUBSTITUTED BENZOFURANS AS ANTIMICROBIAL AGENTS | The University of North Carolina at Chapel Hill (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050197378-A1 | Cationic substituted benzofurans as antimicrobial agents | TIDWELL RICHARD R (US) | 2005-09-08 | — | — | US | disclosed |
| WO-2005055935-A2 | CATIONIC SUBSTITUTED BENZOFURANS AS ANTIMICROBIAL AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2001072742-A1 | BISAMIDINO COMPOUNDS AS NHE-3 INHIBITORS | MERCK PATENT GMBH (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114047-A1 | Cationic substituted benzofurans as antimicrobial agents | BET1, ARG2, BRDT | F2 2791/4885F10 2781/4885PRMT1 1394/4885 |
| US-20050197378-A1 | Cationic substituted benzofurans as antimicrobial agents | BET1, ARG2, BRDT | F2 2791/4885F10 2781/4885PRMT1 1394/4885 |
| US-20080221191-A1 | Cationic substituted benzofurans as antimicrobial agents | BET1, ARG2, BRDT | F2 2791/4885F10 2781/4885PRMT1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.